Information de reference pour ce titreAccession Number: | 00003439-201409000-00018.
|
Author: | Januszyk, Michael 1,2; Sorkin, Michael 1; Glotzbach, Jason P. 1; Vial, Ivan N. 1; Maan, Zeshaan N. 1; Rennert, Robert C. 1; Duscher, Dominik 1; Thangarajah, Hariharan 1; Longaker, Michael T. 1; Butte, Atul J. 3; Gurtner, Geoffrey C. 1,
|
Institution: | (1)Division of Plastic and Reconstructive Surgery, Department of Surgery, Stanford University School of Medicine, Stanford, CA (2)Program in Biomedical Informatics, Stanford University School of Medicine, Stanford, CA (3)Division of Systems Medicine, Department of Pediatrics, Stanford University School of Medicine, Stanford, CA
|
Title: | Diabetes Irreversibly Depletes Bone Marrow-Derived Mesenchymal Progenitor Cell Subpopulations.[Miscellaneous Article]
|
Source: | Diabetes. 63(9):3047-3056, September 2014.
|
Abstract: | Diabetic vascular pathology is largely attributable to impairments in tissue recovery from hypoxia. Circulating progenitor cells have been postulated to play a role in ischemic recovery, and deficiencies in these cells have been well described in diabetic patients. Here, we examine bone marrow-derived mesenchymal progenitor cells (BM-MPCs) that have previously been shown to be important for new blood vessel formation and demonstrate significant deficits in the context of diabetes. Further, we determine that this dysfunction is attributable to intrinsic defects in diabetic BM-MPCs that are not correctable by restoring glucose homeostasis. We identify two transcriptionally distinct subpopulations that are selectively depleted by both type 1 and type 2 diabetes, and these subpopulations have provasculogenic expression profiles, suggesting that they are vascular progenitor cells. These results suggest that the clinically observed deficits in progenitor cells may be attributable to selective and irreversible depletion of progenitor cell subsets in patients with diabetes.
(C) 2014 by the American Diabetes Association, Inc.
|
References: | 1. Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature 2001;414:782-787
2. Annual number (in thousands) of new cases of diagnosed diabetes among adults aged 18-79 years, United States, 1980-2010 [article online], 2010. Available from http://www.cdc.gov/diabetes/stat...- ouverture dans une nouvelle fenêtre. Accessed 14 June 2013
3. Narayan KM, Boyle JP, Geiss LS, Saaddine JB, Thompson TJ. Impact of recent increase in incidence on future diabetes burden: U.S., 2005-2050. Diabetes Care 2006;29:2114-2116
4. Caro JJ, Ward AJ, O'Brien JA. Lifetime costs of complications resulting from type 2 diabetes in the U.S. Diabetes Care 2002;25:476-481
5. Fox CS, Coady S, Sorlie PD, et al.. Increasing cardiovascular disease burden due to diabetes mellitus: the Framingham Heart Study. Circulation 2007;115:1544-1550
6. Moss SE, Klein R, Klein BE. Cause-specific mortality in a population-based study of diabetes. Am J Public Health 1991;81:1158-1162
7. Glotzbach JP, Wong VW, Gurtner GC. Neovascularization in diabetes. Expert Rev Endocrinology 2010;5:99-111
8. Abaci A, Oguzhan A, Kahraman S, et al.. Effect of diabetes mellitus on formation of coronary collateral vessels. Circulation 1999;99:2239-2242
9. Jude EB, Oyibo SO, Chalmers N, Boulton AJ. Peripheral arterial disease in diabetic and nondiabetic patients: a comparison of severity and outcome. Diabetes Care 2001;24:1433-1437
10. Takahashi T, Kalka C, Masuda H, et al.. Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. Nat Med 1999;5:434-438
11. Tepper OM, Capla JM, Galiano RD, et al.. Adult vasculogenesis occurs through in situ recruitment, proliferation, and tubulization of circulating bone marrow-derived cells. Blood 2005;105:1068-1077
12. Ceradini DJ, Gurtner GC. Homing to hypoxia: HIF-1 as a mediator of progenitor cell recruitment to injured tissue. Trends Cardiovasc Med 2005;15:57-63
13. Rafii S, Lyden D. Therapeutic stem and progenitor cell transplantation for organ vascularization and regeneration. Nat Med 2003;9:702-712
14. Semenza GL, Agani F, Booth G, et al.. Structural and functional analysis of hypoxia-inducible factor 1. Kidney Int 1997;51:553-555
15. Ben-Shoshan J, Schwartz S, Luboshits G, et al.. Constitutive expression of HIF-1alpha and HIF-2alpha in bone marrow stromal cells differentially promotes their proangiogenic properties. Stem Cells 2008;26:2634-2643
16. Ceradini DJ, Kulkarni AR, Callaghan MJ, et al.. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat Med 2004;10:858-864
17. Hamou C, Callaghan MJ, Thangarajah H, et al.. Mesenchymal stem cells can participate in ischemic neovascularization. Plast Reconstr Surg 2009;123(Suppl.):45S-55S
18. Velazquez OC. Angiogenesis and vasculogenesis: inducing the growth of new blood vessels and wound healing by stimulation of bone marrow-derived progenitor cell mobilization and homing. J Vasc Surg 2007;45(Suppl A):A39-A47
19. Thangarajah H, Yao D, Chang EI, et al.. The molecular basis for impaired hypoxia-induced VEGF expression in diabetic tissues. Proc Natl Acad Sci U S A 2009;106:13505-13510
20. Lerman OZ, Galiano RD, Armour M, Levine JP, Gurtner GC. Cellular dysfunction in the diabetic fibroblast: impairment in migration, vascular endothelial growth factor production, and response to hypoxia. Am J Pathol 2003;162:303-312
21. El-Ftesi S, Chang EI, Longaker MT, Gurtner GC. Aging and diabetes impair the neovascular potential of adipose-derived stromal cells. Plast Reconstr Surg 2009;123:475-485
22. Tepper OM, Galiano RD, Capla JM, et al.. Human endothelial progenitor cells from type II diabetics exhibit impaired proliferation, adhesion, and incorporation into vascular structures. Circulation 2002;106:2781-2786
23. Ceradini DJ, Yao D, Grogan RH, et al.. Decreasing intracellular superoxide corrects defective ischemia-induced new vessel formation in diabetic mice. J Biol Chem 2008;283:10930-10938
24. Baksh D, Song L, Tuan RS. Adult mesenchymal stem cells: characterization, differentiation, and application in cell and gene therapy. J Cell Mol Med 2004;8:301-316
25. Crosby JR, Kaminski WE, Schatteman G, et al.. Endothelial cells of hematopoietic origin make a significant contribution to adult blood vessel formation. Circ Res 2000;87:728-730
26. Kondo M, Wagers AJ, Manz MG, et al.. Biology of hematopoietic stem cells and progenitors: implications for clinical application. Annu Rev Immunol 2003;21:759-806
27. Massengale M, Wagers AJ, Vogel H, Weissman IL. Hematopoietic cells maintain hematopoietic fates upon entering the brain. J Exp Med 2005;201:1579-1589
28. Balsam LB, Wagers AJ, Christensen JL, Kofidis T, Weissman IL, Robbins RC. Haematopoietic stem cells adopt mature haematopoietic fates in ischaemic myocardium. Nature 2004;428:668-673
29. Wagers AJ, Sherwood RI, Christensen JL, Weissman IL. Little evidence for developmental plasticity of adult hematopoietic stem cells. Science 2002;297:2256-2259
30. Udani VM, Santarelli JG, Yung YC, et al.. Hematopoietic stem cells give rise to perivascular endothelial-like cells during brain tumor angiogenesis. Stem Cells Dev 2005;14:478-486
31. Oswald J, Boxberger S, Jorgensen B, et al.. Mesenchymal stem cells can be differentiated into endothelial cells in vitro. Stem Cells 2004;22:377-384
32. Reyes M, Dudek A, Jahagirdar B, Koodie L, Marker PH, Verfaillie CM. Origin of endothelial progenitors in human postnatal bone marrow. J Clin Invest 2002;109:337-346
33. Wang X, Hisha H, Taketani S, et al.. Characterization of mesenchymal stem cells isolated from mouse fetal bone marrow. Stem Cells 2006;24:482-493
34. Psaltis PJ, Zannettino AC, Worthley SG, Gronthos S. Concise review: mesenchymal stromal cells: potential for cardiovascular repair. Stem Cells 2008;26:2201-2210
35. Silva GV, Litovsky S, Assad JA, et al.. Mesenchymal stem cells differentiate into an endothelial phenotype, enhance vascular density, and improve heart function in a canine chronic ischemia model. Circulation 2005;111:150-156
36. Yue WM, Liu W, Bi YW, et al.. Mesenchymal stem cells differentiate into an endothelial phenotype, reduce neointimal formation, and enhance endothelial function in a rat vein grafting model. Stem Cells Dev 2008;17:785-793
37. Caplan AI. Why are MSCs therapeutic? New data: new insight. J Pathol 2009;217:318-324
38. Crisan M, Yap S, Casteilla L, et al.. A perivascular origin for mesenchymal stem cells in multiple human organs. Cell Stem Cell 2008;3:301-313
39. Kucia MJ, Wysoczynski M, Wu W, Zuba-Surma EK, Ratajczak J, Ratajczak MZ. Evidence that very small embryonic-like stem cells are mobilized into peripheral blood. Stem Cells 2008;26:2083-2092
40. Charbord P. Bone marrow mesenchymal stem cells: historical overview and concepts. Hum Gene Ther 2010;21:1045-1056
41. McEvoy RC, Andersson J, Sandler S, Hellerstrom C. Multiple low-dose streptozotocin-induced diabetes in the mouse. Evidence for stimulation of a cytotoxic cellular immune response against an insulin-producing beta cell line. J Clin Invest 1984;74:715-722
42. Strandell E, Sandler S. In vitro response to interleukin-1 beta and streptozotocin in pancreatic islets isolated from male and female nonobese diabetic mice. J Endocrinol 1997;153:81-86
43. Shibata T, Giaccia AJ, Brown JM. Development of a hypoxia-responsive vector for tumor-specific gene therapy. Gene Ther 2000;7:493-498
44. Glotzbach JP, Januszyk M, Vial IN, et al.. An information theoretic, microfluidic-based single cell analysis permits identification of subpopulations among putatively homogeneous stem cells. PLoS ONE 2011;6:e21211
45. Semenza GL. Surviving ischemia: adaptive responses mediated by hypoxia-inducible factor 1. J Clin Invest 2000;106:809-812
46. Ceradini DJ, Yao D, Grogan RH, et al.. Decreasing intracellular superoxide corrects defective ischemia-induced new vessel formation in diabetic mice. J Biol Chem 2008;283:10930-10938
47. Thangarajah H, Vial IN, Chang E, et al.. IFATS collection: Adipose stromal cells adopt a proangiogenic phenotype under the influence of hypoxia. Stem Cells 2009;27:266-274
48. Kang L, Chen Q, Wang L, et al.. Decreased mobilization of endothelial progenitor cells contributes to impaired neovascularization in diabetes. Clin Exp Pharmacol Physiol 2009;36:e47-e56
49. Kamran P, Sereti KI, Zhao P, Ali SR, Weissman IL, Ardehali R. Parabiosis in mice: a detailed protocol. J Vis Exp 2013;80:e50556
50. Pietramaggiori G, Scherer SS, Alperovich M, Chen B, Orgill DP, Wagers AJ. Improved cutaneous healing in diabetic mice exposed to healthy peripheral circulation. J Invest Dermatol 2009;129:2265-2274
51. da Silva Meirelles L, Caplan AI, Nardi NB. In search of the in vivo identity of mesenchymal stem cells. Stem Cells 2008;26:2287-2299
52. Phinney DG, Hill K, Michelson C, et al.. Biological activities encoded by the murine mesenchymal stem cell transcriptome provide a basis for their developmental potential and broad therapeutic efficacy. Stem Cells 2006;24:186-198
53. Tibshirani R, Walther G, Hastie T. Estimating the number of clusters in a dataset via the gap statistic. J R Statistic Soc B 2001;63:441-423
54. Peichev M, Naiyer AJ, Pereira D, et al.. Expression of VEGFR-2 and AC133 by circulating human CD34(+) cells identifies a population of functional endothelial precursors. Blood 2000;95:952-958
55. Asahara T, Masuda H, Takahashi T, et al.. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res 1999;85:221-228
|
Language: | English.
|
Document Type: | Pathophysiology.
|
Journal Subset: | Clinical Medicine.
|
ISSN: | 0012-1797
|
NLM Journal Code: | e8x, 0372763
|
DOI Number: | https://dx.doi.org/10.2337/db13-...- ouverture dans une nouvelle fenêtre
|
Annotation(s) | |
|
|